The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial introduction generated massive returns, the end of its patent opened the floodgates to generic versions, https://socialioapp.com/story6516675/the-copyright-and-pharma-a-volatile-investment